CSL PEG
PEG omjer (Omjer cijene i earnings rasta) tvrtke CSL (CSL.AX) na dan 1. tra 2026. iznosi 1,58. Prethodne godine PEG omjer (Omjer cijene i earnings rasta) je iznosio 1,79 — promjena od −11,99% (manji).
Get this data via API
Financial Data API
PEG
1,58
YoY
−11,99%
Zadnje ažuriranje:
PEG omjer (Omjer cijene i earnings rasta) tvrtke CSL iznosi 2026 1,58 . PEG omjer (Omjer cijene i earnings rasta) tvrtke CSL iznosio je 2025 1,79 . Pada za −11,99% manji u odnosu na prethodnu godinu.
Access this data via the Eulerpool API
CSL Analiza dionica
Što radi CSL? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country.
CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd.
CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health.
CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products.
In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis.
In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle.
CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field.
The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia.
CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019.
CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL je jedna od najpopularnijih tvrtki na Eulerpool.com.
Često postavljana pitanja o dionici CSL
PEG omjer (Omjer cijene i earnings rasta) od CSL iznosio je 1,79 1,58
Access this data via the Eulerpool API
Vrednovanje — CSL
Sve ključne metrike — CSL
Vrednovanje
Račun dobiti i gubitka
- Prihod
- Brutto dobit
- EBIT
- EBITDA
- Dobit
- Dobit po dionici
- Trošak prodane robe
- Rashodi za istraživanje i razvoj
- Rashodi prodaje, opće i upravnih
- Operativni rashodi
- Rashodi kamata
- Dobit prije poreza
- Porezni rashodi
- Amortizacija i otpisi
- Prihod po dionici
- EBIT po dionici
- Razrijeđeni EPS
- EBITDA po dionici
- Ostali dohodak/rashodi
Marže
Bilanca
- Ukupna imovina
- Kratkoročna imovina
- Novac i ekvivalenti
- Potraživanja
- Inventar
- Nekretnine, postrojenja i oprema
- Goodwill
- Neopipljiva imovina
- Temeljni kapital
- Obveze
- Dugovanje
- Kratkoročne obveze
- Dugoročni dug
- Kratkoročni dug
- Zadržane dobiti
- Knjižna vrijednost po dionici
- Opipljiva knjižna vrijednost po dionici
- Radni kapital
- Ulaganja
- Obveze za isporuke
- Dugoročna sredstva
- Kratkoročne investicije
- Dugoročne investicije
- Neto dug
- Vlastite dionice
- Manjinski udjeli
- Odgođene porezne obveze
- Neto materijalna sredstva
- Goodwill/Sredstva
- Nematerijalna sredstva/Ukupna sredstva
Novčani tok
- Operativni novčani tok
- Kapitalni rashodi
- Slobodan novčani tok
- FCF po dionici
- Isplaćene dividende
- Otkup dionica
- Novčani tok iz investicija
- Novčani tok iz financiranja
- CapEx / Prihod
- Novčani tok po dionici
- Kompenzacija na osnovu dionica
- Promjena radnog kapitala
- Akvizicije (netto)
- Neto promjena gotovine
- CapEx/OCF
- FCF/Neto dobit
- FCF konverzija
- Konverzija gotovine
- Ukupna isplata dioničarima
- CapEx/Amortizacija
Profitabilnost
- ROE
- ROA
- ROCE
- ROIC
- Promet imovine
- Promet inventara
- Promet potraživanja
- Dani prodaje izvanredno
- Dani inventara izvanredno
- Dani obveza izvanredno
- Ciklus konverzije novca
- CROIC
- Bruto dobit/Sredstva
- Koeficijent obrtaja fiksne imovine
- Koeficijent obrtaja vlastitog kapitala
- Koeficijent obrtaja radnog kapitala
- Koeficijent obrtaja obveza
- Intenzivnost kapitala
- Potraživanja/Prihod
- Zalihe/Prihod
- EBIT/Sredstva
Zaduženost
Rast
- Rast prihoda
- Rast prihoda CAGR 3G
- Rast prihoda CAGR 5G
- Rast prihoda CAGR 10G
- Rast dobiti
- Rast EPS-a
- Rast EBIT-a
- EBIT CAGR 3G
- EBIT CAGR 5G
- EBIT CAGR 10G
- Rast dividendi
- Rast slobodnog novčanog toka
- Rast knjižne vrijednosti
- Earnings CAGR 3G
- Earnings CAGR 5G
- Earnings CAGR 10G
- EPS CAGR 3G
- EPS CAGR 5G
- Rast EBITDA godišnje
- EBITDA CAGR 3G
- EBITDA CAGR 5G
- Rast bruto dobitka
- Rast OCF godišnje
- Rast broja zaposlenih
- Dividendni CAGR 3G
- Dividendni CAGR 5G
- Dividendni CAGR 10G
- Rast imovine
- Rast vlastitog kapitala
- Rast duga
- Rast kapitalnih izdataka
- FCF CAGR 3G
- FCF CAGR 5G
- Rast tržišne vrijednosti
- Rast broja dionica